Ignite Creation Date:
2024-05-05 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00487825
Status:
COMPLETED
Last Update Posted:
2012-08-01
First Post:
2007-06-18
Brief Title:
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 26-week Phase II Multi-center Randomized Double-blind Placebo-controlled Study to Assess the Response to Treatment ACR50 and to Determine a Biomarker Profile in Responders to ACZ885 Anti-interleukin-1beta Monoclonal Antibody Plus MTX as Compared to MTX Alone in Early Rheumatoid Arthritis Patients
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was intended to evaluate the safety and efficacy of intravenous IV ACZ885 and oral methotrexate MTX therapy in patients with early rheumatoid arthritis RA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None